EZH2 is overexpressed in laryngeal squamous cell carcinoma and enhances the stem-like properties of AMC-HN-8 cells

Huang,Jiameng; Zhou,Liang; Chen,Hui; Wu,Chunping; Duo,Zhang; Zhang,Yanping

doi:10.3892/ol.2016.4704

EZH2 is overexpressed in laryngeal squamous cell carcinoma and enhances the stem-like properties of AMC-HN-8 cells

Authors:
- Jiameng Huang
- Liang Zhou
- Hui Chen
- Chunping Wu
- Zhang Duo
- Yanping Zhang
View Affiliations

Affiliations: Department of Otolaryngology‑Head and Neck Surgery, Affiliated Eye, Ear, Nose and Throat Hospital of Fudan University, Shanghai 200031, P.R. China, Research Center, Affiliated Eye, Ear, Nose and Throat Hospital of Fudan University, Shanghai 200031, P.R. China
Published online on: June 13, 2016 https://doi.org/10.3892/ol.2016.4704
Pages: 837-846
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The enhancer of zeste 2 polycomb repressive complex 2 subunit (EZH2) histone methyltransferase is the catalytic subunit of polycomb repressive complex 2 (PRC2), which is important for epigenetic regulation. EZH2 is highly expressed in various types of tumors, and its high‑level expression promotes the progression and invasion of certain tumors. However, the expression level of EZH2 and its functions in laryngeal squamous cell carcinomas are unknown. In the present study, the level of EZH2 expression in laryngeal squamous cell carcinomas was evaluated using immunochemical staining and reverse transcription‑quantitative polymerase chain reaction. EZH2 was overexpressed in AMC-HN-8 cells with lentiviral transfection. Cell proliferation, apoptosis, cell‑cycle, chemotherapy‑sensitivity and in vivo tumorigenic assays were performed. The results indicated that EZH2 was highly expressed in laryngeal squamous cell carcinomas. Additionally, EZH2 overexpression promoted proliferation, accelerated cell‑cycle progression and enhanced the tumorigenicity in laryngeal squamous cancer cells. More importantly, EZH2 enhanced the chemotherapy resistance of these cells. Overall, the results indicated that EZH2 promotes the progression of laryngeal squamous cell cancer and could be a potential chemotherapeutic target for the treatment of such cancer.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar : PubMed/NCBI
2	Simon JA and Lange CA: Roles of the EZH2 histone methyltransferase in cancer epigenetics. Mutat Res. 647:21–29. 2008. View Article : Google Scholar : PubMed/NCBI
3	Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C, Morey L, Van Eynde A, Bernard D, Vanderwinden JM, et al: The Polycomb group protein EZH2 directly controls DNA methylation. Nature. 439:871–874. 2006. View Article : Google Scholar : PubMed/NCBI
4	Lee TI, Jenner RG, Boyer LA, Guenther MG, Levine SS, Kumar RM, et al: Control of developmental regulators by polycomb in human embryonic stem cells. Cell. 125:301–313. 2006. View Article : Google Scholar : PubMed/NCBI
5	Ezhkova E, Pasolli HA, Parker JS, Stokes N, Su IH, Hannon G, Tarakhovsky A and Fuchs E: Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells. Cell. 136:1122–1135. 2009. View Article : Google Scholar : PubMed/NCBI
6	Li KQ, Liu C, Zhou BF, Bi L, Huang H, Lin T and Xu K: Role of EZH2 in the growth of prostate cancer stem cells isolated from LNCaP cells. Int J Mol Sci. 14:11981–11993. 2013. View Article : Google Scholar : PubMed/NCBI
7	Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, Luk L, Titley I, Carden CP, Box G, Hudson DL, Kaye SB and Brown R: Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Mol Cancer Ther. 10:325–335. 2011. View Article : Google Scholar : PubMed/NCBI
8	Sobin LH, Gospodarowicz MK and Wittekind C: UICC TNM classification of malignant tumours (7th). Wiley-Blackwell. Oxford: 63–72. 2009.
9	Shi Y, Gong HL, Zhou L, Tian J and Wang Y: CD24: A novel cancer biomarker in laryngeal squamous cell carcinoma. ORL J Otorhinolaryngol Relat Spec. 74:78–85. 2012. View Article : Google Scholar : PubMed/NCBI
10	Zhao LB, Yu Y, Wu J, Bai J, Zhao Y, Li C, Sun W and Wang X: Role of EZH2 in oral squamous cell carcinoma carcinogenesis. Gene. 537:197–202. 2014. View Article : Google Scholar : PubMed/NCBI
11	Blake JL, Runhua S, Vikas M, Glenn M, Federico A and Cherie-Ann ON: Improvements in survival and disparities for advanced-staged laryngeal cancer. JAMA Otolaryngol Head Neck Surg. 141:169–173. 2015. View Article : Google Scholar : PubMed/NCBI
12	Kamminga LM, Bystrykh LV, de Boer A, Houwer S, Douma J, Weersing E, Dontje B and de Haan G: The polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustion. Blood. 107:2170–2179. 2006. View Article : Google Scholar : PubMed/NCBI
13	Juan AH, Derfoul A, Feng X, Ryall JG, Dell'Orso S, Pasut A, Zare H, Simone JM, Rudnicki MA and Sartorelli V: Polycomb EZH2 controls self-renewal and safeguards the transcriptional identity of skeletal muscle stem cells. Gene Dev. 25:789–794. 2011. View Article : Google Scholar : PubMed/NCBI
14	Sher F, Rössler R, Brouwer N, Balasubramaniyan V, Boddeke E and Copray S: Differentiation of neural stem cells into oligodendrocytes: Involvement of the polycomb group protein Ezh2. Stem Cells. 26:2875–2883. 2008. View Article : Google Scholar : PubMed/NCBI
15	Gong Y, Huo L, Liu P, Sneige N, Sun X, Ueno NT, Lucci A, Buchholz TA, Valero V and Cristofanilli M: Polycomb group protein EZH2 is frequently expressed in inflammatory breast cancer and is predictive of worse clinical outcome. Cancer. 117:5476–5484. 2011. View Article : Google Scholar : PubMed/NCBI
16	Wan L, Li X, Shen H and Bai X: Quantitative analysis of EZH2 expression and its correlations with lung cancer patients' clinical pathological characteristics. Clin Transl Oncol. 15:132–138. 2013. View Article : Google Scholar : PubMed/NCBI
17	Wagener N, Macher-Goeppinger S, Pritsch M, Hüsing J, Hoppe-Seyler K, Schirmacher P, Pfitzenmaier J, Haferkamp A, Hoppe-Seyler F and Hohenfellner M: Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma. Bmc Cancer. 10:5242010. View Article : Google Scholar : PubMed/NCBI
18	Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA, Salvesen HB, Otte AP, et al: EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate and breast. J Clin Oncol. 24:268–273. 2006. View Article : Google Scholar : PubMed/NCBI
19	Kidani K, Osaki M, Tamura T, Yamaga K, Shomori K, Ryoke K and Ito H: High expression of EZH2 is associated with tumor proliferation and prognosis in human oral squamous cell carcinomas. Oral Oncol. 45:39–46. 2009. View Article : Google Scholar : PubMed/NCBI
20	Alajez NM, Shi W, Hui AB, Bruce J, Lenarduzzi M, Ito E, Yue S, O'Sullivan B and Liu F: Enhancer of Zeste homolog 2 (EZH2) is overexpressed in recurrent nasopharyngeal carcinoma and is regulated by miR-26a, miR-101 and miR-98. Cell Death Dis. 1:e852010. View Article : Google Scholar : PubMed/NCBI
21	Rao ZY, Cai MY, Yang GF, He LR, Mai SJ, Hua WF, Liao YJ, Deng HX, Chen YC, Guan XY, et al: EZH2 supports ovarian carcinoma cell invasion and/or metastasis via regulation of TGF-beta1 and is a predictor of outcome in ovarian carcinoma patients. Carcinogenesis. 31:1576–1583. 2010. View Article : Google Scholar : PubMed/NCBI
22	Tong ZT, Cai MY, Wang XG, Kong LL, Mai SJ, Liu YH, Zhang HB, Liao YJ, Zheng F, Zhu W, et al: EZH2 supports nasopharyngeal carcinoma cell aggressiveness by forming a co-repressor complex with HDAC1/HDAC2 and Snail to inhibit E-cadherin. Oncogene. 31:583–594. 2012.PubMed/NCBI
23	Crea F, Fornaro L, Bocci G, Sun L, Farrar WL, Falcone A and Danesi R: EZH2 inhibition: Targeting the crossroad of tumor invasion and angiogenesis. Cancer Metast Rev. 31:753–761. 2012. View Article : Google Scholar
24	Chen H, Zhou L, Wan G, Dou T and Tian J: BMI1 promotes the progression of laryngeal squamous cell carcinoma. Oral Oncol. 47:472–481. 2011. View Article : Google Scholar : PubMed/NCBI
25	Suvà ML, Riggi N, Janiszewska M, Radovanovic I, Provero P, Stehle JC, Baumer K, Le Bitoux MA, Marino D, Cironi L, et al: EZH2 Is Essential for glioblastoma cancer stem cell maintenance. Cancer Res. 69:9211–9218. 2009. View Article : Google Scholar : PubMed/NCBI
26	Majewski IJ, Blewitt ME, de Graaf CA, McManus EJ, Bahlo M, Hilton AA, Hyland CD, Smyth GK, Corbin JE, Metcalf D, et al: Polycomb repressive complex 2 (PRC2) restricts hematopoietic stem cell activity. PLoS Biol. 6:e932008. View Article : Google Scholar : PubMed/NCBI
27	van Vlerken LE, Kiefer CM, Morehouse C, Li Y, Groves C, Wilson SD, Yao Y, Hollingsworth RE and Hurt EM: EZH2 is required for breast and pancreatic cancer stem cell maintenance and can be used as a functional cancer stem cell reporter. Stem Cells Transl Med. 2:43–52. 2013. View Article : Google Scholar : PubMed/NCBI
28	McCabe MT, Ott HM, Ganji G, Korenchuk S, Thompson C, Van Aller GS, Liu Y, Graves AP, Della Pietra A III, Diaz E, et al: EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature. 492:108–112. 2012. View Article : Google Scholar : PubMed/NCBI
29	Sasaki H, Setoguchi T, Matsunoshita Y, Gao H, Hirotsu M and Komiya S: The knock-down of overexpressed EZH2 and BMI-1 does not prevent osteosarcoma growth. Oncol Rep. 23:677–684. 2010.PubMed/NCBI
30	Wu Z, Lee ST, Qiao Y, Li Z, Lee PL, Lee YJ, Jiang X, Tan J, Aau M, Lim CZ and Yu Q: Polycomb protein EZH2 regulates cancer cell fate decision in response to DNA damage. Cell Death Differ. 18:1771–1779. 2011. View Article : Google Scholar : PubMed/NCBI
31	Zhang Q, Padi SK, Tindall DJ and Guo B: Polycomb protein EZH2 suppresses apoptosis by silencing the proapoptotic miR-31. Cell Death Dis. 5:e14862014. View Article : Google Scholar : PubMed/NCBI
32	Serguei V and Xin W: Cancer stem cells and drug resistance: The potential of nanomedicine. Nanomedicine. 7:597–615. 2012. View Article : Google Scholar : PubMed/NCBI
33	Hu S, Yu L, Li Z, Shen Y, Wang J, Cai J, Xiao L and Wang Z: Overexpression of EZH2 contributes to acquired cisplatin resistance in ovarian cancer cells in vitro and in vivo. Cancer Biol Ther. 10:788–795. 2010. View Article : Google Scholar : PubMed/NCBI
34	Meng X, Huang Z, Wang R, Jiao Y, Li H, Xu X, Feng R, Zhu K, Jiang S, Yan H and Yu J: The prognostic role of EZH2 expression in rectal cancer patients treated with neoadjuvant chemoradiotherapy. Radiat Oncol. 9:1882014. View Article : Google Scholar : PubMed/NCBI
35	Lu CH, Han HD, Mangala LS, Ali-Fehmi R, Newton CS, Ozbun L, Armaiz-Pena GN, Hu W, Stone RL, Munkarah A, et al: Regulation of tumor angiogenesis by EZH2. Cancer Cell. 18:185–197. 2010. View Article : Google Scholar : PubMed/NCBI
36	Benetatos L, Voulgaris E, Vartholomatos G and Hatzimichael E: Non-coding RNAs and EZH2 interactions in cancer: Long and short tales from the transcriptome. Int J Cancer. 133:267–274. 2013. View Article : Google Scholar : PubMed/NCBI
37	Chen H, Xin Y, Zhou L, Huang JM, Tao L, Cheng L and Tian J: Cisplatin and paclitaxel target significant long noncoding RNAs in laryngeal squamous cell carcinoma. Med Oncol. 31:2462014. View Article : Google Scholar : PubMed/NCBI